Serum S100B As A Potential Biomarker for Cognitive Impairment in Patients with End- Stage Renal Disease. | ||
| Zagazig University Medical Journal | ||
| Articles in Press, Accepted Manuscript, Available Online from 28 October 2025 | ||
| Document Type: Original Article | ||
| DOI: 10.21608/zumj.2025.425938.4209 | ||
| Authors | ||
| Fatma M. Attia Elsayed1; Fatma Ayman Abdelmaksoud* 2; Esameldin Mahmoud Lotfy3; Ibrahim Mohamed Salem4; Hala M Allam4; Safaa Mahmoud Elalawy5 | ||
| 1Lecturer of internal medicine, Faculty of Medicine, Zagazig University, Sharkia, Egypt. | ||
| 2Internal medicine faculty of medicine zagazig univericity | ||
| 3Professor of internal medicine, Faculty of Medicine, Zagazig University, Sharkia, Egypt | ||
| 4Professor of internal medicine, Faculty of Medicine, Zagazig University, Sharkia, Egypt. | ||
| 5Professor of clinical pathology, Faculty of Medicine, Zagazig University, Sharkia, Egypt | ||
| Abstract | ||
| Background: One known side effect of end-stage renal disease (ESRD) and its therapy is cognitive impairment (CI). One well-known neurobiochemical indicator of brain injury is the S100B protein. This study aimed to investigate the potential role of S100B in predicting CI in patients with ESRD. Methods: this cross-sectional study was conducted at the internal medicine department, Zagazig University Hospital on 52 end-stage renal disease patients who attended to hemodialysis unit at Zagazig University Hospital from January 2025 to June 2025. They were classified into two groups according to Mini-Mental State Examination. Group I included (n=31) patients with CI (n=31) while Group II involved ESRD patients without CI (n=21). Full history taking, routine clinical examination and laboratory investigations were applied to all patients. Assessment of urea reduction rate, kt/v and dialysis vintage (month) was done. Mini-Mental State Examination was used to distinguish patient with CI from others without. S100B assessment was performed using the enzyme- linked immunosorbent Results: S100B showed predictive performance for cognitivS100B. It is characterized by an intriguing, unusual impairment with an AUC of 0.7. The best cut-off was 33.00 pg/mL with 70.3% sensitivity and 66.7% specificity. MMSE scores were lower in CI patients, while S100B levels were higher. Conclusion: S100B has great potential in predicting CI in ESRD patients | ||
| Keywords | ||
| S100B; Cognitive Impairment; ESRD and MMSE | ||
|
Statistics Article View: 8 |
||
